Targeting therapeutic vulnerabilities with PARP inhibition and radiation in IDH-mutant gliomas and cholangiocarcinomas
Open Access
- 24 April 2020
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (17), eaaz3221
- https://doi.org/10.1126/sciadv.aaz3221
Abstract
Mutations in isocitrate dehydrogenase (IDH) genes occur in multiple cancer types, lead to global changes in the epigenome, and drive tumorigenesis. Yet, effective strategies targeting solid tumors harboring IDH mutations remain elusive. Here, we demonstrate that IDH-mutant gliomas and cholangiocarcinomas display elevated DNA damage. Using multiple in vitro and preclinical animal models of glioma and cholangiocarcinoma, we developed treatment strategies that use a synthetic lethality approach targeting the reduced DNA damage repair conferred by mutant IDH using poly(adenosine 5′-diphosphate) ribose polymerase inhibitors (PARPis). The therapeutic effects are markedly enhanced by cotreatment with concurrent, localized radiation therapy. PARPi-buttressed multimodality therapies may represent a readily applicable approach that is selective for IDH-mutant tumor cells and has potential to improve outcomes in multiple cancers.Funding Information
- National Institutes of Health (R01 CA177828)
- National Institutes of Health (P30 CA008748)
This publication has 46 references indexed in Scilit:
- miR-34a Repression in Proneural Malignant Gliomas Upregulates Expression of Its Target PDGFRA and Promotes TumorigenesisPLOS ONE, 2012
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeNature, 2012
- IDH mutation impairs histone demethylation and results in a block to cell differentiationNature, 2012
- IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumoursThe Journal of Pathology, 2011
- Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic DifferentiationCancer Cell, 2010
- Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract CancerThe New England Journal of Medicine, 2010
- Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia GenomeThe New England Journal of Medicine, 2009
- Radiation Therapy Is Associated With Improved Survival in the Adjuvant and Definitive Treatment of Intrahepatic CholangiocarcinomaInternational Journal of Radiation Oncology*Biology*Physics, 2008
- An Integrated Genomic Analysis of Human Glioblastoma MultiformeScience, 2008
- Loss of Arf causes tumor progression of PDGFB-induced oligodendrogliomaOncogene, 2007